Abstract: Although, lanthanum carbonate has not been approved
by the FDA for treatment of hyperphosphatemia, we prospectively
evaluated the efficacy of the combination of Calcium hydroxyapatite
(CHAp) and Lanthanum Carbonate (LaC) for the treatment of
hyperphosphatemia on mice. CHAp was prepared by co-precipitation
method using Ca(OH)2, H3PO4, NH4OH with calcination at 1200ºC.
Lanthanum carbonate was prepared by chemical method using
NaHCO3 and LaCl3 at low pH environment, below 4.0. The
structures were characterized by FTIR spectra and SEM -EDX
analysis. The study group included 16 subjects-mice divided into four
groups according to the administered substance: lanthanum carbonate
(group A), CHAp (group B), lanthanum carbonate + CHAp (group C)
and salt water (group D). The results indicate a phosphate decrease
when subjects (mice) were treated with CHAp and lanthanum
carbonate (0.5% CMC), in a single dose of 1500 mg/kg. Serum
phosphate concentration decreased [(from 4.5 ± 0.8 mg/dL) to
4.05 ± 0.2 mg/dL), P < 0.01] in group A and in group C (to 3.6
± 0.2 mg/dL) at 12 hours from the administration. The combination
of CHAp and lanthanum carbonate is a suitable regimen for
hyperphosphatemia treatment because it avoids both the
hypercalcemia of CaCO3 and the adverse effects of CHAp.